Cargando…
A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer
Anaplastic thyroid carcinoma (ATC) is a rare, but devastating disease. Despite multimodal approaches combining surgery, chemotherapy and radiation therapy, ATC is associated with a dire prognosis, with a median overall survival of only three to ten months. Novel treatments are thus urgently needed....
Autores principales: | Ljubas, Josip, Ovesen, Therese, Rusan, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678800/ https://www.ncbi.nlm.nih.gov/pubmed/31277524 http://dx.doi.org/10.3390/cancers11070943 |
Ejemplares similares
-
Salutary Response to Targeted Therapy in Anaplastic Thyroid
Cancer
por: Fazeli, Sasan, et al.
Publicado: (2019) -
Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management
por: Yuan, Jiaqian, et al.
Publicado: (2022) -
Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review
por: Salehian, Behrouz, et al.
Publicado: (2019) -
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
por: Wirth, Lori J., et al.
Publicado: (2021) -
The role of chemotherapy and latest emerging target therapies in anaplastic thyroid
cancer
por: Denaro, Nerina, et al.
Publicado: (2013)